問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Veterans General Hospital

List

2200Cases

2018-02-08 - 2018-02-08

Phase III

A Randomized, Global, Open-label Study of Nivolumab in Combination With BMS-986205 vs Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

  • Condition/Disease

    Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

  • Test Drug

    BMS-986205/Nivolumab

Participate Sites
3Sites

Terminated3Sites

2015-12-01 - 2016-12-23

Phase III

An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based Fist Line Chemotherapy

  • Condition/Disease

    Small-cell Lung Cancer

  • Test Drug

    Nivolumab

Participate Sites
4Sites

Terminated3Sites

夏德椿
China Medical University Hospital-Taipei

未分科

2017-05-01 - 2023-10-30

Phase III

Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy

  • Condition/Disease

    NSCLC

  • Test Drug

    Nivolumab (BMS-936558),Ipilimumab (BMS-734016)

Participate Sites
16Sites

Terminated14Sites

黃煦晴
Taipei Veterans General Hospital

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2013-01-16 - 2015-07-01

Phase III

A Phase 3 evaluation of daclatasvir in combination with peginterferon lambda-1a and ribavirin (RBV) or telaprevir in combination with peginterferon alfa-2a and RBV in patients with chronic hepatitis C genotype 1b who are treatment naïve or prior relapsers to alfa/RBV therapy(The STRUCTURE Study)

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BMS-914143/ BMS-790052

Participate Sites
6Sites

Terminated6Sites

2015-11-01 - 2020-02-17

Phase III

A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naive

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Abatacept

Participate Sites
4Sites

Terminated4Sites

郭昶甫
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2015-07-01 - 2023-10-27

Phase III

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

  • Condition/Disease

    Renal Cell Carcinoma

  • Test Drug

    Nivolumab (BMS-936558)

Participate Sites
3Sites

Terminated3Sites

黃逸修
Taipei Veterans General Hospital

Division of Hematology & Oncology

張文震
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2014-07-01 - 2015-12-31

Phase III

A Phase 3 Study of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects with Chronic Hepatitis C Genotype 1 (UNITY 4)

  • Condition/Disease

    Chronic Hepatitis C Genotype 1

  • Test Drug

    Daclatasvir/Asunaprevir/BMS-791325; Film coated tablet; 30 mg/200 mg/75 mg (as the free base)

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

彭成元
China Medical University Hospital

Digestive System Department

2021-10-21 - 2022-11-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2019-11-30 - 2024-07-31

Phase III

A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mLOPDIVO (nivolumab) Injection 10mg/mLYERVOY (ipilimumab) Injection 5mg/mLYERVOY (ipilimumab) Injection 5mg/mL

Participate Sites
9Sites

Recruiting9Sites

2018-10-01 - 2021-08-31

Phase II

A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

  • Condition/Disease

    Advanced Pancreatic Cancer

  • Test Drug

    Cabiralizumab (BMS-986227, FPA008)

Participate Sites
2Sites

Terminated2Sites

李重賓
Taipei Veterans General Hospital

Digestive System Department

1 211 212 213 214 215 220
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB